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The stimulation of human platelets by thrombin leads to the activation of phospholipases C and A,. protein kinases, formation of Sinositol phos- 
pholipids and mobiiization of CaZ’. These biochemi~dl reactions closely parallel platelet shape change. granular secretion and aggregation. The 
Inembrane-bou~~d transducers For the thrombin receptor seem to be the heterotr~meric G protein G,z and the tw-related G protein rap I-b. Phospho- 
rylation of rap I-b by the action of the cyclic AMP-dependent protein kinase seems to uncouple the thrombin receptor from phosphoiipases, This 
causes inhibition of the formation of second messenger molecules and the onset of physiological responses. 
Fieterotrimeric G protein: Small molecular weight G protein: Phospholipase C; Phospholipase A,: Sinositol phosphoiipid: Protein kinase A 
1. INTRODUCTION 
Thrombin is a potent agonist that elicits platelet 
physiological responses such as shape change, granular 
content secretion, and aggregation. The cellular 
transduction of thrombin action includes the activation 
of thrombin receptor-associated GTP-binding proteins 
and the subsequent stimulation of phospholipase C and 
phospholipase A2 [I]. The products of these phos- 
pholipases generate specific biochemical messengers. 
For instance, phospholipase C causes the breakdown of 
inositol phospholipids and the production of 
1,2-diacylgiycerol, which activates protein kinase C [2], 
and inositol 1,4,5-trisphosphate 131, which mobihzes 
Cal* from the endoplasmic reticulum to the cytosol. 
The increase of cytosolic CaZ + activates 
Ca2 ’ -dependent enzymes such as myosin light-chain 
kinase [I]. The stimulation of phospholipase AZ also 
results in production of active molecules. The libera- 
tion of arachidonic acid from the 2-position of various 
phospholipids will generate aI-achidonate-derived 
metabolites through the cyclooxygenase and lipox- 
ygenase activities 141. These include the endoperoxides 
and thromboxanes, which can efficiently induce further 
platelet activation [4]. This chapter discusses fun- 
damental aspects of the various signal transduction 
steps in the binding of thrombin to platelets. 
2. MEMBRANE-BOUND TRANSDUCER 
The membrane-bound transducer between the recep- 
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tor and the phospholipase in the thror~lbin-induced 
platelet response seems to be a specific ~TP-binding 
protein (G protein), which is functionally referred to as 
Gp [S]. The exact identity of this protein has not yet 
been determined. G proteins were originally described 
by their ability to affect adenylyl cyclase (G, stimulates 
this enzyme while Gi inhibits) or cyclic GMP 
phosphodiesterase (Gr stimulates this enzyme in the 
visual system) [6-g]. These G proteins have a 
heterotrimeric structure consisting of cy, /3, and y 
subunits. Other heterotrimeric G proteins, such as G, 
and G,, have been identified [6-81. In each case the CY 
subunit binds GTP and possesses an intrinsic GTPase 
activity. In addition, these CY subunits can be specifical- 
ly ADP-ribosyIated by cholera toxin (cy,), by pertussis 
toxin (ai, ao), by both toxins (cu,), or not affected by 
toxin-induced ADP-ribosylation (cw,) [6-S]. Several 
species of G,, and Gi,, have been described [6-S]. For 
Gicy, it is possible to distinguish three distinct proteins; 
these are referred to as Girrr, G;,l and Giirr3 [9]. The 
three are about 90% identical and are locaiized in 
specific tissues [9]. The fl subunit of the heterotrimeric 
G proteins corresponds to one or the other of closely 
related 3% and 36-kDa proteins, whereas the y subunit 
is a low molecular mass protein (M, 6000-10 000) [6-S]. 
It is known that the interaction of the receptor with a 
heterotrimeric G protein induces dissociation of the cy 
subunit with release of the by subunit [6-81. ln- 
vestigators have implicated Gi in the modulation of 
phospholipase C in those cases where pertussis toxin in- 
hibits the agonist-induced stimulation of phospholipase 
C [9]. G, has been postulated as a mediator for activa- 
tion of phospholipase C through a pertussis toxin- 
insensitive pathway [9]. Moreover, a recent publication 
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Fig. 2. ~~e~~bolism of in&tides and inositol phosphates. 
Pbu~~bat~d~l~nositol (PtdIns) can be sequential& phosphoryi~~ed by 
specific kinases to phosphatid~li~ositul ~jnonophosphat~ (Ptdlns4Pf 
and phosphatidylinositol 4,Sbisphosphate (PtdIns4,SPz). The 
potyphosphoinositides cart also be dephospborylated by specific 
phosphomonoesterases. A specific inositide-phospholipase C 
(phosphoinositidase) can hydrolyze the inositol phospholipids to 
inasitol ~-monophospbate <lnslP), inositnl ~,4-bisphosp~late 
(Insl,4P& and inositol i ,4,Wriphosphate (Ins1,4,5P1). The three in- 
o&ides can also be phosphorylated by a specific phosphatidylinositol 
Skinase to produce the respective Sinositides: phosphatid~lir;ositol 
3-monophosphate (Ptdlns3P), phosphatidylinositol3,4-bisphosphate 
(PtdIns3,4Pz), and phosphatidylinositoi 3,4,Striphosphate 
(Ptdl~s3.4~~F~~. lnositoi l.4,~-trispho~phat~ (fn~l,4,%~1) can be se- 
quentially dephosphorylated to inositol 1,4-b&phosphate (Insl,4P:), 
inositol 4-monophosphate (It&P), and inositol (Ins). Insl,4.SP~ can 
alternatively be ~bosp~~or~la~ed by a 3-kinase to inositof 
1,3,4,5_tetrakisphosphate (lns1,3,4,SP4), which, in turn, can be 
dephosphorylared to inositol 1,3,4-t&phosphate (Insl,3,4P9 or 
Insl,it,SP?. Ins1,3,4P, is dephosphorylat~d to inositol 
I ,3-bisphosphafe (Ins1 ,~Pz) or inositol 3.4.hisphosphate (Ins3,4P2). 
lnsl.3P: seems to be sequentially dephosphor~l~ted to inositoi 
l-monopbosp~~ate ffnslP) and Ins, shereas tns3,4Pz is 
dephosphorylated to inositol 3-monophosphate flns3P) and Ins. 
to form phosphatidylinositol 4,5-bisphosphate. The in- 
terconversion of the inositol phosphoiipids and the 
derived inositol phosphates produced by phospholipase 
C is depicted in Fig. 2 131. A kinase, inositol 
I ,4,~-tr~sphosphate S-kinase, can further 
phosphorylate inositol 1,4,%trisphosphate to form in- 
ositol ~,3,4,5-tetrak~sphosphate [3]. AIi the inositof 
phosphates shown in Fig. 2 are dephosphoryfated by 
different inositoi phosphatases leading to the forma- 
tion of inositof as shown in Fig. 2 131. fnositot 
1,4,5-trisphosphat~ and inositol 1,3,4,5_tetrakisphos- 
phate are d~phosphoryfated by the same enzyme, a 
5-phosphatase 131. Inositol 1,3,4,5-tetrakisphosp~lat~ 
has also been shown to be dephosphoryiated to inositol 
1,4,%trisphosphate by a 3-phosphatase, which is ac- 
tivated by thrombin and phorbol ester [21]. 
4, T~RO~~~~ PRODUCES NOVEL POL>YPHOS- 
PHOlNOSITIDES, THE 3-INOSfTOL PHOS- 
PHOLIPIDS, IN HUMAN PLATELETS 
Recent reports have documented phosphatidyl- 
inositol 3-kinase activity in different cells that is 
regulated by receptor occupation and results in 
phosphoinositides ph~sphorylated at the 3-position on 
the inositol ring (Fig. 2) f22]. Such inositoi 
phospholil9~ds may act as novel second messengers 
themselves since they are not substrates fot 
phospholipase C [23]. The phosphatidyli~osi~o~ 
3-kinase in NIH-3T3 cells is specifically associated with 
middle Tipp60c-‘i” protein from middle T-transformed 
ceIIs as welI as with antiphosphotyrosine im- 
munoprecipitates from platelet-derived growth factor- 
stimulated fibrobtasts [22]. Platelets contain abundant 
levels of a pp@Y“-related protein-tyrosine kinase, 
which in human plateiets is activated by thrombi1~ treat- 
ment f24]. Thrombin stimulates the formation of 
pllosphatidyli~~ositol 3,4-bis~?hosp~at~ nd phosphati- 
dyI~nos~to1 3,4,5-trisphosphate in human pfatelets 
[25,X]. The level of phospha~idylinositol 
3,4-b~sphosphate is also increased by thrombin in 
human er~~throl~ukemia cells that posses a number of 
p~ateIet-Iike f atures [27]. These novel lipids appear to 
represent an as yet u~lcharacteri~ed branch of the in- 
ositide cycle in activated platetets and may be involved 
in transmembrane signaling in activated platelets. In 
other proliferating cells, they have been implicated in 
transduction of the mitogenic signal. The role, if any, 
of ppW‘“” in the formation of the 3-inositol 
phospho~ip~ds in platelets has yet to be eiu~idated. 
5. ACTrV.~~I~~ OF PHOSPHOL.IPASE At 
Thrombin is very active in releasing arachidonic acid 
from membrane phospho~ipids of platelets {1,4]. The 
primary enzymes responsible for this activation are 
phospholi~ase AZ and, to a Iesser degree, 
I ,2-diacylglycerol ipase [ lY4]. Thrombin activation of 
platelets depends on arachidonic acid release only at 
low concentrations of thrombin; at higher doses the 
ability of thrombin to activate platelets is independent 
of arachidon~c acid metabolites [1,4]. The most impor- 
tant arachidonic acid metabolites in platelet stimulation 
are endoperoxides and thromboxane AZ. These prod- 
ucts are derived from the concerted action of cycloox- 
ygenase and thromboxane synthase. 
lit has been widely accepted that CaZi’ mobi~i~at~o~ 
- a consequence of phospholipase C activation - is a 
prerequisire for the ac~~~~ation of phosphol~~~ase AZ 
t1,41. However, there are indications that 
ph~spho~ipase AZ is not under the control of the 
prevailing Ca2 * Ievef in the intact cell (28J, Collagen 
has been shown to activate phospholipase Az in- 
dependently of changes in the cellular Ca”’ concentra- 
tion (291. Also, the ability of ~-thromb~n to induce the 
release of Ca’+ stores does not parallel the liberation 
of arachidonic acid [28]. This suggests that 
ph~sphol~pase C activation and phosphol~pase Az ac- 
tivation are separate vents in pfateiet activation. Also, 
the mechanism by which ru-thrombin stimulated 
402 
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pbosphol~pase AZ does not appear to be through 
dissociation of the inhibitory G protein, Gi, since a- 
thrombin decreases the pertussis toxin-induced ADP- 
ribosylation of ai as much as does cY-thrombin, but is 
much less effective than ~-thrombin at inducing 
ara~h~donic a id liberation 1281. 
The reg~Iation of phos~hoIipase AZ is not yet 
understood. It is possible that the concerted action of 
CaZi , protein kinase C, and Gi dissociation controf 
phospholipase AZ activation in platelets. However, it is 
possible to rule out the existence of a single controlling 
factor of ara~hidoni~ acid liberation in this cell. 
6. lN~~3~TION OF PLATELET RESPONSES 
It is widely known that the increase of platelet cyclic 
AMP (CAMP) inhibits ail platelet responses to ac- 
tivating factors including activation of ph~spholipases 
C and A2 i[l]. The exact rn~c~~a~isrn of this effect is not 
well understood but it is believed to be related to the 
phosphoryl~tio~ of specific proteins by CAMP- 
dependent protein kinase [l J. The inhibition of 
thrombin~induc~d phospholipase C by cAMP is also 
observed in the human ~rythroleukemi~ (NFL) cell 
[17]. A specific protein is phosphorylated by the action 
of cAMP in both cefls, This is a 22-kDa protein that 
binds ICY-““PfGTP on nitroceltulose blots and displays 
strong reactivity with the monoclonal antibody M90 
[I&-f8f. This antibody recognises an epitope between 
amino acids 107 and I30 of the H-ras p2f protein, 
which is one of the major GTP-binding regions of the 
protein. Elevation of intracellular cAMP Ieveis in 
platelets and HEL cells by the prostacyciin analog il- 
oprost results in a shift of the apparent molecular mass 
of the M90 irn~~unorea~ti~~ band from 22 kDa to 24 
k&t. This shift correlates with translo~ation of the 
modified 22 kDa protein from a particulate to a 
cytosolic fraction ff4,1.5], It is proposed that these 
changes in the mobiIity of the 22-kDa protein are the 
result of a covalent modification of the protein such as 
~hosphorylation. Indeed, the treatment of 32P-labeIed 
platelets with iloprost results in the phosphorylation of 
a 2% to 24-kDa GTP-binding protein by CAMP- 
dependent protein kinase f14]. This phosphorylated 
protein can be immuno~recipitated with the mono- 
clonal antibody M90 fI4,15], suggesting that the 
22-kDa translocated protein and the phosphoryla~e~ 
protein are identical 
Amino acid analysis of the peptides obtained by 
digestion of the 22-kDa protein with trypsin or 
Sraphybcoccus aureus V8 protease has shown that the 
phospho~yIated protein is rapl-b [I&]. Three rap pro- 
teins have so far been identified and they all are about 
50% identical with ras 130,311. They are extensively 
homuiogo~s with rm at the GTP-bindj~g region and 
the effector domain. They also contain a carboxyl- 
terminal CAAX motif that is thought to be essential for 
processing and membrane locafization. Rapl-a (aiso 
called smg-21 1321 or Krev-I 1331) has been shown to 
reverse the transformed phenotype of ~~~-t~a~sforrned 
cells 1331. Rapl-b is the major substrate for 
ph~sphorylation by cyclic AMP-dependent protein 
kinase in platelets and human erythrolenkemia cells 
[lS]. Rap2 is membrane-bound and is isoprenylated 
(urlpublisbed resufts). Since cAMP inhibits phospho- 
lipase C, it is possible that the phosphorylation and 
translocation of rapl-b has a significant role in the 
regulation of phospholipase C (and or phosphoIi~ase 
AZ). The U~phosphoryIated rapt-b may be closely 
associated with phosphoIipase C (Fig. 1). Upon 
phosphorylation and translo~ation of rapi-b, 
phosphoiipase C may lose the ability to be stimulated by 
thrombin or other agonists (Fig. 1). The confirmation 
of this hypothesis awaits further investigation. 
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